Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Lilly (LLY) Down 3.7% Since Last Earnings Report: Can It Rebound?
Published: March 06, 2026 by: Zacks Investment Research
Sentiment: Negative
Lilly (LLY) reported earnings 30 days ago. What's next for the stock?
Read More
What Are The Biggest Risks To Eli Lilly Stock?
Published: March 05, 2026 by: Forbes
Sentiment: Negative
Eli Lilly stock (LLY) is currently trading near $1,000, reflecting a decline of over 11% from its 52-week high as investors recalibrate expectations against emerging headwinds.
Read More
Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear?
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Neutral
LLY's shares fall 5% in a month amid pricing fears and obesity-drug rivalry, but booming Mounjaro and Zepbound sales and a deep pipeline keep growth hopes alive.
Read More
Forget AI. This Biotech Stock's Taking Off Right Now
Published: March 04, 2026 by: 24/7 Wall Street
Sentiment: Positive
The market seems to be falling heavily out of love with the AI stocks, and for good reason: CapEx is rising at a staggering rate, especially among the Mag Seven AI darlings, all while the question marks surrounding ROIs get bigger.
Read More
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
Published: March 04, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Baron Health Care Fund Q4 2025 Contributors And Detractors
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Positive
Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the company in a $9.2 billion all-cash deal announced in November 2025, representing a premium of more than 100% over the prior closing price. Doximity's stock detracted from performance as the company issued disappointing guidance for the next two quarters.
Read More
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Published: March 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata
Published: March 02, 2026 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly wins CHMP backing to expand Olumiant use in adolescents with severe alopecia areata, with the EU approval decision expected shortly.
Read More
Why Novo Nordisk's Ireland expansion is key to fighting off Eli Lilly
Published: March 02, 2026 by: CNBC
Sentiment: Positive
Novo Nordisk is investing $506 million to expand manufacturing capabilities in Ireland. The move will strengthen its ability to meet both current and future demand for its oral medicines, said Novo executive Kasper Bødker Mejlvang.
Read More
What Smart Money Loves About Lilly
Published: March 02, 2026 by: 24/7 Wall Street
Sentiment: Neutral
Eli Lilly (NYSE: LLY) stock has pulled back 2.9% year-to-date to around $1,044, and institutional investors have been accumulating shares during the pullback, according to recent filings.
Read More
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
Published: March 02, 2026 by: Zacks Investment Research
Sentiment: Positive
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.
Read More
Why Eli Lilly is Winning the Weight Loss War
Published: February 27, 2026 by: Wall Street Journal
Sentiment: Positive
WSJ's David Wainer breaks down why Novo Nordisk struggled and Eli Lilly prospered in the weight loss drug market. #
Read More
5 US Blue Chip Giants That Have Paid Dividends for Over 100 Years
Published: February 27, 2026 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.
Read More
Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
Published: February 27, 2026 by: PRNewsWire
Sentiment: Neutral
The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeks The study is the first and largest of its kind specifically designed to evaluate children and adolescents with severe AA, a disease that has devastating social and emotional impact Lilly has also submitted Olumiant in the U.S. for approval to treat severe AA in adolescents, with a decision expected in the second half of 2026 INDIANAPOLIS, Feb. 27, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) …
Read More
Columbia Balanced Fund Q4 2025 Contributors And Detractors
Published: February 25, 2026 by: Seeking Alpha
Sentiment: Positive
Lilly delivered exceptional performance over the period, driven by sustained strength in its diabetes and obesity portfolio. Applied Materials outperformed during the quarter, as AI-driven wafer-fab investment and advanced packaging needs sustained orders and backlog visibility. BlackRock underperformed during the period, as margin pressures and valuation concerns overshadowed otherwise strong fundamentals.
Read More
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
Published: February 25, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead?
Published: February 25, 2026 by: Zacks Investment Research
Sentiment: Positive
LLY's Mounjaro and Zepbound drove 56% of revenues in 2025 as obesity demand surged, with new launches and Medicare access set to fuel growth.
Read More
Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Neutral
LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.
Read More
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen
Published: February 23, 2026 by: CNBC
Sentiment: Positive
Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some patients, as it reduces the number of devices they have to use in a month to take the drug.
Read More
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
Used by millions of patients worldwide, the KwikPen® for single-patient use provides patients with a new option to receive Zepbound® Zepbound patients can access all doses in either multi-dose KwikPen or single-dose vial at the same self-pay price, starting at $299, available by prescription now through LillyDirect* INDIANAPOLIS, Feb. 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that delivers a full month of treatment in one device. With the Zepbound KwikPen, Lilly is expanding choice …
Read More
Novo Nordisk's next obesity drug falls short of Lilly rival, wiping billions off its market value
Published: February 23, 2026 by: Proactive Investors
Sentiment: Negative
Novo Nordisk (NYSE:NVO) attempt to reclaim the initiative in the obesity drug race has backfired, after its experimental next-generation treatment failed to prove it was as effective as a rival therapy from Eli Lilly. The Danish drugmaker's shares were off 14% ahead of the bell in the US (it fell as much as 15% in Europe), after it disclosed that CagriSema did not meet its primary objective of demonstrating non-inferiority to Lilly's tirzepatide in terms of weight loss over 84 weeks.
Read More
Novo Nordisk pitted a new weight-loss drug against Eli Lilly — and lost
Published: February 23, 2026 by: Market Watch
Sentiment: Negative
Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn't cut as much weight as an Eli Lilly product.
Read More
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial
Published: February 23, 2026 by: CNBC
Sentiment: Negative
The drug, CagriSema, didn't achieve its primary endpoint of demonstrating non-inferiority on weight loss. In this article NVO
Read More
Novo Nordisk's obesity drug falls short against Eli Lilly's in Copenhagen trial
Published: February 23, 2026 by: Reuters
Sentiment: Negative
Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly's Tirzepatide in reducing body weight.
Read More
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)
Published: February 19, 2026 by: PRNewsWire
Sentiment: Neutral
Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years Additional new data revealed exceptionally low surgery and hospitalization rates in Omvoh-treated patients across both Crohn's disease and ulcerative colitis (UC), underscoring its potential to fundamentally change disease trajectory Omvoh now stands alone as the only IL-23p19 inhibitor to show strong and durable efficacy with simple, consistent monthly dosing over four years in UC and three years in Crohn's disease INDIANAPOLIS, Feb. 19, 2026 /PRNewswire/ -- New long-term data from Eli Lilly and Company (NYSE: LLY) showed Omvoh …
Read More
1 Reason I'd Buy Eli Lilly Stock and Never Sell
Published: February 17, 2026 by: The Motley Fool
Sentiment: Positive
Eli Lilly has been busy building its drug pipeline for the future. The company currently sells the world's best-selling drug.
Read More
Why Eli Lilly's $1 Billion AI Bet Could Reshape Drug Discovery
Published: February 16, 2026 by: 24/7 Wall Street
Sentiment: Positive
As of February 13, 2026, shares of Eli Lilly (NYSE:LLY) were trading at $1,040, just 5.8% below the stock's all-time high.
Read More
Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors
Published: February 16, 2026 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly is included due to its strategic positioning with respect to sustainability opportunities, specifically in HealthCare Access and Innovation. Advanced Micro Devices is owned for its exceptional Corporate Resilience profile and attractive sustainability opportunity set in areas like the Digital Infrastructure build-out. Oracle stands out with a strong sustainability profile, offering notable opportunities in Digital Infrastructure, Education and the development of Enhanced Skills & Innovation.
Read More
Lilly to participate in TD Cowen's 46th Annual Health Care Conference
Published: February 16, 2026 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS, Feb. 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice president and chief financial officer, will take part in a fireside chat at 3:10 p.m.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000